Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Supplementary Information from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Supplementary Methods from A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Oza AM. et al, (2023)

Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Table S2 from The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers

Hu Z. et al, (2023)

Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.

Blagden SP. et al, (2023), Br J Cancer, 128, 474 - 477

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.

Jones R. et al, (2023), Clin Cancer Res, 29, 331 - 340

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis EJ. et al, (2022), J Immunother Cancer, 10

A qualitative exploration of digital medicines information usage: Insights from an evaluation of the BNF

Blagden S. et al, (2022), Health Policy and Technology, 11

Interventions delivered in secondary or tertiary medical care settings to improve routine vaccination uptake in children and young people: a scoping review.

Blagden S. et al, (2022), BMJ Open, 12

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Clamp AR. et al, (2022), Lancet Oncol, 23, 919 - 930

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.

Nicum S. and Blagden SP., (2022), Clin Cancer Res, 28, 2201 - 2203

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Pantziarka P. and Blagden S., (2022), Cancers (Basel), 14

Targeting MAPK in recurrent, low-grade serous ovarian cancer.

Blagden SP., (2022), Lancet, 399, 499 - 501

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.

Schwenzer H. et al, (2021), Clin Cancer Res, 27, 6500 - 6513

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

Kazmi F. et al, (2021), Cochrane Database of Systematic Reviews, 2021

OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.

Frangou E. et al, (2021), Gynecol Oncol, 162, 431 - 439

A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.

Kazmi F. et al, (2021), Clin Cancer Res, 27, 3028 - 3038

A qualitative exploration of the barriers to and facilitators of clozapine monitoring in a secure psychiatric setting.

Blagden S. et al, (2021), BJPsych Bull, 45, 134 - 140

1
2
3
4
5
6
7
...
»